Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Inflammatory Carcinoma
Interventions: DRUG: Dasatinib|DIETARY_SUPPLEMENT: Icosapent Ethyl
Sponsor: National Cancer Institute (NCI)